查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1541405

2024-2032 年按產品類型、應用、最終用途和地區分類的放射性藥物市場報告

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球放射性藥物市場規模達到55億美元。放射性藥物市場主要由影像技術的新興技術進步、慢性病發病率的增加以及全球政府實施有利的監管標準所推動。

放射性藥物市場分析：

主要市場促進因素：根據放射性藥物市場研究報告，該市場主要受到慢性病發病率不斷上升的推動，主要是癌症和心血管疾病。此外，包括 PET 和 SPECT 在內的影像技術的進步，隨著這些放射性藥物在診斷方面的使用激增，改變了診斷技能。

主要市場趨勢：該行業正在形成的趨勢是人們越來越偏好治療診斷學，即相同的化合物可用於診斷和治療。此外，放射性藥物產業概況顯示了對研發（R&D）的投資，以引入新型放射性藥物，以提高療效並最大限度地減少副作用。

地理趨勢：由於強大的醫療基礎設施、高支出和支持性的監管環境，北美地區引領全球市場。由於衛生支出的增加以及對核醫學益處的認知的增加，預計包括中國和印度在內的亞太新興經濟體將快速成長。

競爭格局：放射性藥物產業的一些主要市場參與者包括 Advanced Accelerator Applications (Novartis AG)、Bayer AG、Bracco SpA、Cardinal Health Inc.、Curium Pharma、General Electric Company、IBA RadioPharma Solutions、Jubilant Pharma Limited、Lantheus Medical Imaging Inc、Nordion Inc. (Sotera Health)、NTP Radioisotopes SOC Ltd、PharmaLogic Holdings Corp. 和西門子AG 等。

挑戰與機會：放射性藥物核准過程與監管挑戰相關，例如製造過程的複雜性和安全威脅。然而，放射性藥物市場預測良好，市場參與者前景良好。人們對個人化醫療的興趣日益濃厚，以及放射性藥物作為標靶治療的一部分的出現，促進了市場的成長。透過與科研院所的合作、企業間的合作，為醫藥企業提供了廣大的市場開拓機會。

放射性藥物市場趨勢：

成像技術的技術進步：

正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等影像技術的進步極大地增強了放射性藥物的診斷性質。使用這些技術對於腫瘤學、神經學和心臟病學中需要早期治療或預防措施的疾病進行早期診斷至關重要。例如，2023 年，正子斷層掃描 (PET) 的全球市場價值約為 119.61 萬美元。目前，根據 IMARC GROUP 的預測，到 2032 年，全球正子斷層掃描 (PET) 市場預計將成長至約 19.3 億美元，2024 年至 2032 年的年複合成長率(CAGR) 為 5.33%。這一成長歸功於成像技術的進步以及這些先進系統在世界各地醫療診斷中的實施。

慢性病盛行率增加：

由於全球癌症、心血管疾病和神經系統疾病的盛行率不斷上升，對放射性藥物的需求不斷增加，推動了市場的成長。這些疾病需要準確的診斷影像和針對性的治療，促使放射性藥物在臨床實踐中的使用。根據疾病管制與預防中心 2020 年的資料，美國報告了 1,603,844 例新發癌症病例，並因此不幸失去了 602,347 人的生命。這相當於每 10 萬人中有 403 例新癌症病例和 144 例癌症相關死亡。目前，放射性藥物用於癌症早期檢測和治療所需的診斷和治療應用，從而推動市場成長。

有利的監管環境：

該行業受到政府行為和監管規定的顯著影響。例如，美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構根據國家醫學圖書館的規定，提出即時有效的程序來批准新開發的放射性藥物，鼓勵創新和投資。除此之外，對藥物類別進行快速虛擬審查的可能性，以及獲得孤兒藥指定 (ODD) 狀態的經濟激勵，激勵許多製藥公司參與新放射性藥物療法的研發 (R&D)。

放射性藥物市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品類型、應用和最終用途對市場進行了分類。

按產品類型分類：

診斷核子醫學

治療核子醫學

診斷核醫學佔大部分市場佔有率

該報告根據產品類型對市場進行了詳細的細分和分析。這包括診斷核子醫學和治療核子醫學。報告稱，診斷核子醫學佔最大部分。

診斷核子醫學是指使用通常用於影像的多種放射性藥物。它結合了不同的模式，例如正子斷層掃描（PET）。這同樣適用於單光子發射電腦斷層掃描 (SPECT)。由於癌症、心臟異常和其他神經疾病等疾病盛行率的增加，診斷核醫市場在未來幾年必定會擴大。目前，那格浦爾政府醫學院和醫院（GMCH）和超級專科醫院（SSH）正準備透過設立專門的核子醫學部門來提高其診斷能力。今年，該部門的提案獲得了地區規劃委員會 (DPC) 的批准，預算為 9.5 億盧比。由於行政部分已經整理完畢，部門建設即將啟動。

按應用分類：

腫瘤學

心臟病學

神經病學

內分泌科

其他

腫瘤學佔產業最大佔有率

報告還提供了基於應用程式的詳細市場細分和分析。這包括腫瘤學、心臟病學、神經學、內分泌學等。報告稱，腫瘤學佔據最大的市場佔有率。

由於癌症標靶治療和精準醫療市場的快速成長，放射性藥物的腫瘤學應用需求不斷成長。放射性藥物對於透過 PET 和 SPECT 掃描等方式進行癌症的診斷、分期和治療後評估至關重要。這也歸因於不斷擴大的放射腫瘤學市場，據 IMARC GROUP 稱，該市場預計到 2032 年將達到 145 億美元，2024-2032 年期間的複合年成長率 (CAGR) 為 6.5%。除此之外，為提高腫瘤學放射性藥物的可行性和安全性而進行的持續研究和開發工作預計將推動該行業的發展勢頭。

按最終用途細分：

醫院和診所

研究所

診斷中心

診斷中心代表領先的細分市場

該報告根據最終用途提供了詳細的市場細分和分析。這包括醫院和診所、研究機構和診斷中心。根據該報告，診斷中心佔最大部分。

診斷中心是最大的細分市場，正在創造有利的放射性藥物市場前景。為了實現對各種醫療狀況的準確診斷，對核子造影程序的需求不斷成長，導致了診斷中心的採用。它使用各種成像技術，例如正電子發射斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT) 和混合成像，以確保良好的患者治療效果。因此，各個主要參與者正在引入先進的診斷技術，這進一步擴大了放射性藥物的市場價值。例如，2022 年 12 月，領先的醫學影像技術公司 Polarean Imaging plc 宣布美國食品藥物管理局 (FDA) 批准了 XENOVIEW。它是一種超極化造影劑，適用於磁振造影 (MRI)，以評估成人和 12 歲及以上兒童患者的肺部通氣。 XENOVIEW 代表了肺部醫學的新時代，因為它是第一種吸入式 MRI 超極化造影劑。它使得獲得肺部通氣的新穎可視化成為可能，而無需使患者暴露於電離輻射及其相關風險。它透過 Polarean HPX 超極化系統進行管理，XENOVIEW 在一次 10-15 秒屏氣 MRI 練習中進行分配。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔據最大的放射性藥物市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是放射性藥物最大的區域市場。

由於強大的醫療基礎設施、高額醫療支出、技術進步以及市場上擁有眾多產品的成熟企業的存在，北美在市場上佔據主導地位。根據醫療保險和醫療補助服務中心的數據，2022 年美國醫療保健支出成長 4.1%，達到 4.5 兆美元，高於 2021 年 3.2% 的增幅。歷史新高），私人醫療保險投保人數增加了290 萬人，醫療補助參保人數增加了610 萬人。此外，政府的高額資助和支持以及疾病盛行率的增加也推動了市場的成長。因此，這促進了該行業的創新，並加速了新的有效產品的推出，從而提高了放射性藥物市場的成長率。

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。放射性製藥業的一些主要市場參與者包括 Advanced Accelerator Applications (Novartis AG)、Bayer AG、Bracco SpA、Cardinal Health Inc.、Curium Pharma、通用電氣公司、IBA RadioPharma Solutions、Jubilant Pharma Limited、Lantheus Medical Imaging Inc.、 Nordion Inc. (Sotera Health)、NTP Radioisotopes SOC Ltd、PharmaLogic Holdings Corp. 和西門子AG。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

目前，放射性藥物市場的主要參與者都參與了各種策略性舉措，以維持其市場地位和立足點。這些措施包括研發投資，以開發和創新具有更高功效和安全性的新放射性藥物產品。除了研究、開發和創新外，兩家公司還參與策略合作和夥伴關係，以擴大其產品線和分銷網路。例如，2023 年 11 月，總部位於威斯康辛州的融合技術公司 SHINE Technologies 最近與 Nucleus RadioPharma 簽訂了長期供應協議，供應鎧 177。放射性同位素用於癌症治療療法，包括正在開發的神經內分泌腫瘤、前列腺癌和其他實體腫瘤的療法。幾年來，SHINE 將供應 Lu-177 以支持 Nucleus RadioPharma 的放射性配體治療 (RLT) 產品，該產品針對專門針對神經內分泌腫瘤和前列腺癌設計的放射性藥物治療。一些主要參與者也參與增強和最佳化製造生產流程，以滿足對放射性藥物不斷成長的需求，符合即將推出和現有的監管標準。

放射性藥物市場新聞：

2023 年 3 月：國際原子能總署 (IAEA) 與 11 所日本大學和機構合作發起「希望之光」合作夥伴關係，旨在加強亞太地區的癌症照護服務。

2024 年 2 月：百時美施貴寶完成了對 RayzeBio 的收購，透過獨特的基於錒的放射性藥物平台增強了其產品組合。此次新增也引入了放射性藥物治療（RPT），它正在成為治療患者實體瘤的成長最快的治療方式之一。

本報告回答的關鍵問題

  • 2023年全球放射性藥物市場規模是多少
  • 2024-2032年全球放射性藥物市場的預期成長率是多少
  • COVID-19 對全球放射性藥物市場有何影響
  • 推動全球放射性藥物市場的關鍵因素是什麼
  • 根據產品類型，全球放射性藥物市場的細分如何
  • 基於應用的全球放射性藥物市場的細分是什麼
  • 根據最終用途，全球放射性藥物市場的詳細情形如何
  • 全球放射性藥物市場的重點區域有哪些
  • 誰是全球放射性藥物市場的主要參與者/公司

本報告回答的關鍵問題

  • 2023年全球放射性藥物市場規模有多大？ 2024-2032年全球放射性藥物市場的預期成長率是多少？
  • COVID-19 對全球放射性藥物市場有何影響？
  • 推動全球放射性藥物市場的關鍵因素是什麼？
  • 根據產品類型，全球放射性藥物市場的詳細情形如何？
  • 根據應用，全球放射性藥物市場的詳細情形如何？
  • 根據最終用途，全球放射性藥物市場的詳細情形如何？
  • 全球放射性藥物市場的重點區域有哪些？
  • 誰是全球放射性藥物市場的主要參與者/公司？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球放射性藥物市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品類型

  • 診斷核子醫學
    • 市場趨勢
    • 市場預測
  • 治療核子醫學
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按應用

  • 腫瘤學
    • 市場趨勢
    • 市場預測
  • 心臟病學
    • 市場趨勢
    • 市場預測
  • 神經病學
    • 市場趨勢
    • 市場預測
  • 內分泌科
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：最終用途別

  • 醫院和診所
    • 市場趨勢
    • 市場預測
  • 研究所
    • 市場趨勢
    • 市場預測
  • 診斷中心
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Advanced Accelerator Applications (Novartis AG)
    • Bayer AG
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium Pharma
    • General Electric Company
    • IBA RadioPharma Solutions
    • Jubilant Pharma Limited
    • Lantheus Medical Imaging Inc
    • Nordion Inc. (Sotera Health)
    • NTP Radioisotopes SOC Ltd
    • PharmaLogic Holdings Corp.
    • Siemens AG
Product Code: SR112024A3906

The global radiopharmaceuticals market size reached US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The radiopharmaceuticals market is primarily driven by the emerging technological advancements in imaging technology, the increasing incidences of chronic ailments, and the implementation of favorable regulatory standards by the government across the globe.

Radiopharmaceuticals Market Analysis:

Major Market Drivers: As per the radiopharmaceuticals market research report, the market is predominantly driven by the growing incidence of chronic diseases, mainly cancer and cardiovascular disorders. Additionally, advances in imaging procedures including PET and SPECT alter the diagnosis skill with the surging use of these radiopharmaceuticals for diagnostic perspectives.

Key Market Trends: The trend that is taking shape in the industry is the growing preference for theranostics, where the same compound can be used for diagnosis and therapy. Furthermore, the radiopharmaceuticals industry overview shows investments in research and development (R&D) to introduce novel radiopharmaceuticals to inflate efficacy and minimize side effects.

Geographical Trends: The North America region leads the global market as a result of the strong healthcare infrastructure, high expenditure, and supportive regulatory environment. It is also expected that emerging economies in Asia-Pacific including China and India will grow rapidly due to the increase in health expenditure and awareness concerning the benefits of nuclear medicine.

Competitive Landscape: Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG, among many others.

Challenges and Opportunities: The radiopharmaceutical approval process is associated with regulatory challenges, such as the complexity of manufacturing processes and safety threats. However, the radiopharmaceuticals market forecast is favorable and market players have good prospects. The growing interest in personalized medicine and the emergence of radiopharmaceuticals as a component of targeted therapy contribute to the market growth. It offers vast opportunities for market development through collaboration with research institutes and intercompany cooperation for pharmaceutical enterprises.

Radiopharmaceuticals Market Trends:

Technological Advancements in Imaging Technologies:

The advancements in imaging technologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), have highly enhanced the diagnostic nature of radiopharmaceuticals. It is vital in the early diagnosis of conditions that require early treatment or preventive measures in oncology, neurology, and cardiology, using these technologies. For instance, in 2023, the global market for positron emission tomography (PET) was valued at approximately $1.196.1 Million. Presently, the global positron emission tomography (PET) market is projected to grow to about $1.93 billion by 2032, with a compound annual growth rate (CAGR) of 5.33% from 2024 through 2032, according to forecasts by the IMARC GROUP. The growth is attributed to advances in imaging technology and the implementation of these advanced systems in medical diagnostics across the world.

Increasing Prevalence of Chronic Diseases:

The market growth is driven by the increasing demand for radiopharmaceuticals due to the rising prevalence of cancer, cardiovascular diseases, and neurological disorders worldwide. These diseases necessitate accurate diagnostic imaging and focused therapeutics, prompting the utilization of radiopharmaceuticals in clinical practice. According to CENTERS for DISEASE CONTROL AND PREVENTION data in 2020, the United States witnessed the reporting of 1,603,844 new incidences of cancer and the unfortunate loss of 602,347 lives due to the disease. This equates to a rate of 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Currently, radiopharmaceuticals are used in diagnostic and treatment applications necessary for the early detection and treatment of cancers, thus driving market growth.

Favorable Regulatory Environment:

The industry is significantly impacted by governmental actions and regulatory provisions. For instance, regulatory authorities such as the U.S. FOOD AND DRUG ADMINISTRATION (FDA) and the EUROPEAN MEDICINES AGENCY (EMA) present instant and effective procedures to approve newly developed radiopharmaceuticals encouraging innovation and investment as per the NATIONAL LIBRARY of MEDICINE. Besides this, the possibility of a rapid virtual review of drug classes, along with financial incentives for obtaining Orphan Drug Designation (ODD) status, motivates many pharmaceutical companies to engage in research and development (R&D) of new radiopharmaceutical therapies.

Radiopharmaceuticals Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, application, and end use.

Breakup by Product Type:

Diagnostic Nuclear Medicine

Therapeutic Nuclear Medicine

Diagnostic nuclear medicine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes diagnostic nuclear medicine and therapeutic nuclear medicine. According to the report, diagnostic nuclear medicine represented the largest segment.

Diagnostic nuclear medicine refers to the administration of a diverse number of radiopharmaceuticals typically used for imaging. It incorporates different modalities such as positron emission tomography (PET). The same also applies to single-photon emission computed tomography (SPECT). Due to the observed increase in the prevalence of diseases including cancer, cardiac abnormalities, and other neuronal conditions, the diagnostic nuclear medicine market is bound to expand in the coming years. At present, the Government Medical College and Hospital (GMCH) and the Super Speciality Hospital (SSH) in Nagpur are preparing to elevate their diagnostic capabilities by launching a dedicated nuclear medicine department. The proposal for this department was approved by the District Planning Committee (DPC) this year with a 9.5 crore budget. Since the administrative part has been sorted, the construction of the department is to be initiated soon.

Breakup by Application:

Oncology

Cardiology

Neurology

Endocrinology

Others

Oncology holds the largest share of the industry

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes oncology, cardiology, neurology, endocrinology, and others. According to the report, oncology accounted for the largest market share.

Oncology applications in radiopharmaceuticals are experiencing rising demand, facilitated by the rapid growth of the targeted cancer therapies and precision medicine market. Radiopharmaceuticals are crucial in the diagnosis, staging, and post-treatment evaluation of cancers through PET and SPECT scans, among other modalities. This is also attributed to the expanding radiation oncology market which is expected to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032 as stated by IMARC GROUP. Apart from this, ongoing research and development efforts to improve the feasibility and safety of radiopharmaceuticals in oncology are anticipated to boost the momentum of the sector.

Breakup by End Use:

Hospitals and Clinics

Research Institutes

Diagnostic Centers

Diagnostic centers represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end use. This includes hospitals and clinics, research institutes, and diagnostic centers. According to the report, diagnostic centers represented the largest segment.

Diagnostic centers represent the largest segment and are creating a favorable radiopharmaceuticals market outlook. The rising demand for nuclear imaging procedures to achieve an accurate diagnosis of various medical conditions resulted in the adoption of diagnostic centers. It uses various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging to ensure a favorable patient outcome. Hence various key players are introducing advanced diagnostic technologies which is further expanding the radiopharmaceuticals market value. For instance, in December 2022, Polarean Imaging plc, a leading medical imaging technology company, announced that the U.S. Food and Drug Administration (FDA) approved XENOVIEW. It is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) to assess lung ventilation in adults and pediatric patients 12 years of age and older. XENOVIEW represents a new era of pulmonary medicine since it is the very first inhaled MRI hyperpolarized contrast agent. It makes it possible to obtain a novel visualization of lung ventilation without exposing the patient to ionizing radiation and its associated risks. It is administered via the Polarean HPX hyperpolarization system, XENOVIEW is dispensed in a single 10-15 second breath hold MRI practice.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest radiopharmaceuticals market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiopharmaceuticals.

North America is dominating the market due to the presence of strong healthcare infrastructure, high healthcare spending, technological advancements, and the presence of established players within the market with numerous product offerings. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, United States health care spending grew 4.1% to reach $4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Moreover, in 2022, the insured share of the population reached 92% (a historic high) and private health insurance enrollment increased by 2.9 million individuals and Medicaid enrollment increased by 6.1 million individuals. In addition, high government funding and support, as well as an increasing prevalence of disease, are also driving the market growth. Hence, this promotes innovation within the sector and accelerates the introduction of new and effective products generating an increasing radiopharmaceuticals market growth rate.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Currently, key players in the radiopharmaceuticals market are involved in various strategic initiatives to sustain their market positions and footholds. These initiatives include research and development investments to develop and innovate new radiopharmaceutical products with enhanced efficacies and safety. In addition to research, development, and innovation, the companies are also involved in strategic collaborations and partnerships to expand their product pipeline and distribution networks. For instance, in November 2023, SHINE Technologies, a fusion technology company based in Wisconsin, has recently entered a long-term supply agreement with Nucleus RadioPharma to supply lutetium-177. A radioisotope is utilized in cancer treatment therapies, including those under development for neuroendocrine tumors, prostate cancer, and other solid tumors. For several years, SHINE will supply Lu-177 to support Nucleus RadioPharma's radioligand therapy (RLT) offerings, which target radiopharmaceutical treatments specifically designed for neuroendocrine tumors and prostate cancer. Some key players are also involved in enhancing and optimizing manufacturing production processes to meet the growing demand for radiopharmaceuticals in line with upcoming and existing regulatory standards.

Radiopharmaceuticals Market News:

March 2023: The INTERNATIONAL ATOMIC ENERGY AGENCY (IAEA) initiates the Rays of Hope partnership in collaboration with 11 Japanese universities and institutions which aims to bolster cancer care services across Asia and the Pacific region.

February 2024: Bristol Myers Squibb finalized the acquisition of RayzeBio, enhancing its portfolio with a distinctive actinium-based radiopharmaceutical platform. This addition also introduces radiopharmaceutical therapeutics (RPTs), which are emerging as one of the most rapidly growing treatment modalities for addressing solid tumors in patients.

Key Questions Answered in This Report

  • 1. What was the size of the global radiopharmaceuticals market in 2023?
  • 2. What is the expected growth rate of the global radiopharmaceuticals market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global radiopharmaceuticals market?
  • 4. What are the key factors driving the global radiopharmaceuticals market?
  • 5. What is the breakup of the global radiopharmaceuticals market based on the product type?
  • 6. What is the breakup of the global radiopharmaceuticals market based on the application?
  • 7. What is the breakup of the global radiopharmaceuticals market based on the end use?
  • 8. What are the key regions in the global radiopharmaceuticals market?
  • 9. Who are the key players/companies in the global radiopharmaceuticals market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiopharmaceuticals Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Diagnostic Nuclear Medicine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Nuclear Medicine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endocrinology
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Diagnostic Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Advanced Accelerator Applications (Novartis AG)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bracco S.p.A.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Cardinal Health Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Curium Pharma
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 General Electric Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 IBA RadioPharma Solutions
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Jubilant Pharma Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lantheus Medical Imaging Inc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Nordion Inc. (Sotera Health)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 NTP Radioisotopes SOC Ltd
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 PharmaLogic Holdings Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Siemens AG
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Radiopharmaceuticals Market: Major Drivers and Challenges
  • Figure 2: Global: Radiopharmaceuticals Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Radiopharmaceuticals Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Radiopharmaceuticals Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Radiopharmaceuticals Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Radiopharmaceuticals Market: Breakup by End Use (in %), 2023
  • Figure 7: Global: Radiopharmaceuticals Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Radiopharmaceuticals (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Radiopharmaceuticals (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Radiopharmaceuticals (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Radiopharmaceuticals (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Radiopharmaceuticals (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Radiopharmaceuticals (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Radiopharmaceuticals (Endocrinology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Radiopharmaceuticals (Endocrinology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Radiopharmaceuticals (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Radiopharmaceuticals (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Radiopharmaceuticals (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Radiopharmaceuticals (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Radiopharmaceuticals (Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Radiopharmaceuticals (Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Radiopharmaceuticals (Diagnostic Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Radiopharmaceuticals (Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Radiopharmaceuticals Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Radiopharmaceuticals Industry: SWOT Analysis
  • Figure 78: Global: Radiopharmaceuticals Industry: Value Chain Analysis
  • Figure 79: Global: Radiopharmaceuticals Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiopharmaceuticals Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Radiopharmaceuticals Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Radiopharmaceuticals Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Radiopharmaceuticals Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 5: Global: Radiopharmaceuticals Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Radiopharmaceuticals Market: Competitive Structure
  • Table 7: Global: Radiopharmaceuticals Market: Key Players